Monthly Archives: April 2020

‘She Never Died’ Quietly Resurrected on VOD in Canada – Bloody Disgusting

Posted on by

FilmmakerJason Krawczykmade a name for himself with his 2014-15 festival hitHe Never Died, which starredHenry Rollins as Jack, a social outcast who embarks on a bloody quest to save his long-lost daughter from a crime syndicate.

Director Audrey Cummings put her own spin on the premise with the female-led follow-up, titled She Never Died, which quietly released today on VOD platforms in Canada via A71 Entertainment. Its available throughApple TV, Bell, Rogers, Sasktel,Shaw and Telus.

The new film, written by Jason Krawczyk, starsOlunike Adeliyi(Chaos Walking) as the title character, Lacey, a socially detached loner cursed with immortality. In her attempts to keep her compulsions in check, she seeks out the darkest souls humanity has to offer.

Lacey must now face her own inner demons while simultaneously finding her next meal.

Here are the official trailer and art for the Canadian release. Theres still no word on a U.S. distributor.

Original post:
'She Never Died' Quietly Resurrected on VOD in Canada - Bloody Disgusting

What We Do in the Shadows: Everything You Need to Know for Season 2 – CBR – Comic Book Resources

Posted on by

The first season of What We Do in the Shadows hit FX last year with little fanfare but managed to build a sizable audience through word of mouth. Based on the 2014 film of the same name, the series is a mockumentary that follows a group of vampires who live in Staten Island.

Instead of trying to modernize vampires, the series offers a satirical take on the classic idea of them. They have powers like flight and immortality but still have restrictions like not being able to go into sunlight. Isolated from other vampires and barely interacting with the human world, theyre stuck facing theproblems oftheir supernaturalyet suburban lives.

RELATED: Why Thor: Ragnarok Fans Will Love FX's What We Do In the Shadows

With Season 2 premiering April 15, there are a lot of people excited to start the show, and there are fans who need a quick refresher. Heres everything you need to know about the show heading into Season 2.

Formerly a soldier of the Ottoman Empire, Nandor considers himself the leader of the group yet often remains oblivious to what other people are up to. Hes interested in the human world but fails to grasp an understanding of it.

Nadja, a Romani vampire, is often the most competent of the group and does her own thing, keeping the rest of them out of the loop.This includes reuniting withher reincarnated lover and turning a college student into a vampire.

RELATED: Mark Hamill to Guest Star on What We Do in the Shadows

Rounding out the main trio, Laszlos a former English Nobleman who Nadja turned into a vampire and then married. He often disagrees with Nandors leadership and acts on passion more than logic. He also frequently works on artistic projects such as music andlawnart.

Guillermo, while not a vampire, has been Nandors familiar for 10 years.Acting as familiar is a form of servitude thats supposed topay off whenNandorturnsGuillermo into a vampire, which has yet to happen. He constantly expresses disappointmentover this, butit flies over Nandors head. At the end of Season 1, Guillermo hasfound out that hes a descendent of Van Helsing, the infamous vampire hunter.

Colin Robinson is not part of the main tri0 per say because he is a different form of vampire than the others, known as an energy vampire. Instead of blood, he drains peoples energythrough tactics likelong, boring conversations. Everyone else in the house avoids him because of this. Since he can go out in sunlight, he works an office job and has thebest understanding of human life.

RELATED: Taika Waititi Helming Two Animated Charlie & the Chocolate Factory Series

While theres plenty of stuff that happens in Season 1, these are the events that may have an impact on Season 2, including the consequences of the Baron's death. At the beginning of the season, the house takes in the Baron, who demands they rule over America. After Guillermo accidentally kills him, the Vampiric Council finds the trio guilty of murder; however, Guillermo and Colin Robinson rescue them before their execution.

Another plot thread to pick up on is the undead life of Jenna. Taking pity on the virgin Guillermo wanted to give the group as a special treat, Nadja turns the girl, Jenna, into a vampire. Nadja then spends some time training Jenna, but she has yet to master all her vampire abilities.

RELATED: Taika Waititi Jokes He's Quitting Film to Take Up... Sewing

There is also the time the houseis assignedthe dauntingtask ofhosting the bi-annual vampire orgy. Thingsgo south as theyaren'table to get everything together, and the virgin ends up having sex before anyonecan sink their teeth into him. This is a great shame for the entire house.

Finally there is Gregor, Nadja's reincarnated lover. In the modern day he is rebornas a man named Jeff. At the end of the season Laszlo reveals hes known about this and beheads him.

What We Do in the Shadows stars Kayvan Novak, Natasia Demetriou, Mark Proksch, Matt Berry and Harvey Guillen. Taika Waititi co-produces alongside Jemaine Clement, Scott Rudin, Paul Simms and Garrett Basch. A 10-episode second season premieres on April 15, 2020.

KEEP READING: What We Do in the Shadows' Vampire Marriage is 'Very Millennial'

Forget Goku & Vegeta: Dragon Ball's ULTIMATE Saiyan Was WAY More Powerful

More here:
What We Do in the Shadows: Everything You Need to Know for Season 2 - CBR - Comic Book Resources

Rory McIlroy: ‘A Different Masters’ May Be ‘What I Need To’ Win the Green Jacket – Bleacher Report

Posted on by

Phelan M. Ebenhack/Associated Press

Rory McIlroy believes the postponement of the Masters because of the coronavirus pandemic could work to his advantage.

The Masters will now be played Nov. 12-15 rather than in April, and McIlroy said during an appearance on Nike Golf's Instagram Live on Sunday (h/t Brentley Romine of GolfChannel.com) that the change could be beneficial to him:

"I feel like there's anticipation going to Augusta, the first big event of the year. There's all this hype. I don't think it'll feel like that this year.I think it'll feel a little bit different, which I'm looking forward to.It's going to be a different Masters, and personally, selfishly, maybe that's what I need to get the [green]jacket."

The 30-year-old McIlroy has won each of the other three major tournaments and is a four-time major champion overall, but he is a Masters win away from completing the career Grand Slam.

McIlroy's best Masters finish is fourth, but he has landed inside the top 10 in five of his past six outings at Augusta. He finished a distant 15th in 2011 after holding the 54-hole lead, fading badly with a final-round 80.

Despite all of McIlroy's success, that failure has loomed large in his career, and winning a green jacket may be the only way to erase it.

With the way the 2020 Masters is scheduled, the PGA Championship and U.S. Open will have already been played,provided play is able to resume by the summer.

McIlroy believes that could help him be in his desired rhythm come Masters time:

"November is going to be different. It's going to be cold. The course can play very long. I mean, it plays long already, but it could play very long. The greens might not be as fast as they usually are in April, depending on the moisture. Obviously, they can do whatever they want with the course with SubAir and everything, but I think it'll be a different feel as well. It's the back end of the year as two of the majors have already been playedhopefully, the Ryder Cup's already been played. People might be in their routines and in their flow a little bit."

McIlroy is a one-time Open Championship winner who is capable of conquering adverse weather conditions. That is to be expected of a player who hails from Northern Ireland.

Also, Romine noted that nine of McIlroy's 18 career PGA Tour wins have come in August or later, which suggests he gets better as the season goes on.

McIlroy has often been in the mix at the Masters over the past several years, but perhaps a change in scheduling and weather is what he needs to get over the top and cement his place in golf immortality forever.

BleacherReport's David Gardner interviews athletes and other sports figures for the podcastHow to Survive Without Sports. In this episode, MLB outfielder Dexter Fowler.

The rest is here:
Rory McIlroy: 'A Different Masters' May Be 'What I Need To' Win the Green Jacket - Bleacher Report

(Book) love in a time of corona – The Bookseller

Posted on by

Like many other people these days, I do doorstep deliveries.

Sherlock Holmes to the boy at no.16 who told me he likes mysteries.Love, Nina to the northern friend in exile who finds herself cooking endless meals for a large and eccentric cast of characters (in this case her own children). A picture encyclopaedia to another friends son who sensationally complains of actually missing school. And a brand-new copy of A Tree Grows in Brooklyn from my own gift stash for Evelyn, my oldest customer, who is finding the days very long.

This last drop was a three-way operation involving a 24-hour buffer zone, anti-bacterial wipes, and another neighbour as go-between as both Evelyn and I were self-isolating at the time.

Evelyn sent the go-between neighbour back to me with a large cabbage as a thank you.The most surreal thing thats happened to me all week, reported go-between neighbour by text.

This is community book box meets Camus The Plague (currently being reprinted in Japan to meet a surge in demand).

No one has handed Camus in here yet, but a Joe Wicks shaht aht to the person who optimistically donated Kunderas Immortality. Instantly got borrowed.

I opened a Little Free Library outside my house on my birthday back in January. Bright yellow, planted underneath with matching miniature daffodils, two shelves for grown ups, a big upright section for the childrens picture books, Perspex door for easy browsing, and the Little Free Library slogan Take a Book Share a Book on the front.

According to the Little Free Library official world map,its the only one in Cambridge.

And it was a gloomy time in this safe Labour ward, populated with heartbroken Remainers, academics, internationals, young families and students (some households ticking all these boxes simultaneously). Yup, Guardian Central, remarked a police inspector friend, not unkindly.

So, early January 2020. How could it get worse?

(Right.)

But, back then, with my weatherproofed box on a stick,I was fighting back. Back against Brexit, and library cuts, and general grump and people not looking up from their phones as they trudged past my door to Tesco's. Fighting back against the children in my road, and roads everywhere, being told not to touch, and not to wonder, and that nothing good ever came for free.

Free books! In January! With daffodils! What's not to love?

Well, not everyone loved it.

One waspy woman buzzed down her car window to ask if I'd got planning permission for "that horrible contraption". Someone stole the comments book. Someone asked if it was a speed camera. Other people (the same person?) left a chemistry text book and a recipe book of 1970s buffet food.In German.

Under cover of darkness another reader, either catastrophically misreading the demographic or trying wickedly to provoke it, left a paperback Seventy-Two Virgins by one Boris Johnson. (Effortlessly brilliant page-turner gasps the Daily Telegraph).

I curated this straight back out and shared a photo of it with my two best friends in the road. Burn it! came the response seconds later.

But the joy of the thing has not left me.Indeed, if anything it has grown.

In three months I have got to know more of my neighbours than I have in the past three years. Ive had glorious, hug yourself with delight, pavement chats with the archivist at Newnham College who now makes special detours past the library with her grand-daughter; as well as with the man carrying a load of gardening equipment who screeched to a halt in front of my house and gasped I dont BELIEVE it!

Are you pleased? I asked nervously, still stung from Wasp Woman.

Pleased?! he roared, Im DELIGHTED!

There was the kinetic bundle of secondary school kids who abandoned their bikes on the pavement to ask is this, like, actually free? Before the virus shut the schools, 4.30pm had become their time to visit.Lurking unobserved in my kitchen, I huffed with pleasure to see how carefully they were selecting picture books for younger siblings. Now, not in uniform, they come all the time. If anyone has a stock of Wimpy Kids, Wilson and Walliams, call me now.

A good librarian knows her customers, and Im getting there. On occasion Im actually too good, offering back Alain De Bottons The Architecture of Happiness to my design-minded neighbour Jessica who had, in fact, donated it hours before. Youd love this! I said.

I know. I do, came the response. But Im only keeping the hardback.

Annoyingly, I have yet to find the right coffee table for Shack Chic: Art and Innovation in South African Shack-Lands.

Geekily, I refreshed the entire stock on World Book Day but didnt have time to make the planned fanfare with balloons and poster, so Im not sure anyone noticed.

Gloriously, one pre-virus teatime when my sons friend embarks on an elaborate narrative about her grandparents in Spain having millions of tortoises at home, I am able to shriek Wait there! before dashing outside to retrieve Esio Trot.

And its Christmas every day now when I return with my boys from a government-sanctioned walk to find cardboard fruit boxes full of teen favourites, or three supermarket bags seeping with crime novels. Who left those?! A mystery

Enforced community spring cleaning equals a doorstep bonanza. With conventional bookshops and libraries closed, and Amazon judging reading requirements as non-essential in these testing times, the Little Free Library is the only show in town. And its keeping us all going in ways I never expected when I began.

Closing my curtains at night, I see people browsing by the light of their phones (note to self: install solar panel?).When I get given a collection of phonics texts for early readers, I let my neighbour Rachel know.With a restless five-year-old who is already over the whole home-schooling adventure, somehow wandering down to choose her own story from the library makes it easier to keep sounding those letters out.

In the past fortnight Ive been offered bread for books, and veg for books, and now people are leaving jigsaws and DVDs and games in the library with notes attached saying things like Hope this is fun for someone xxx.

When I myself developed coronavirus symptoms, my younger son shot up the hierarchy to chief librarian. Do not, I rasped, propped on boiling pillows, use special books from Mummys shelf or your own shelves to re-stock the library, ok? Just look in the red refills box downstairs .

Exeunt helpful five-year-old.To a location quite possibly Not Downstairs.Lucky neighbours.

COVID-19 has changed us all. But in this small corner of a quarantined city, so has the Little Free Library. And its quite the page-turner.

View post:
(Book) love in a time of corona - The Bookseller

Aaron Smith is reaching out for a "Brother" in a time of need – EARMILK

Posted on by

It seems almost impossible to imagine a reality that is darker or more pervasive than the one we are currently facing, but in times of global solidarity, the little voices that have always tried to speak out seem to be drowned out even more. While the whole world is coming to terms with its own flaws and immortality, this state of uncertain anguish is one many others have already been facing, with Scotland native Aaron Smith bringing their stories to light in his new single "Brother."

/p>

After releasing his debut EPLoveless, it seemed that the world was at his feet, having gone on to perform in sold out shows in London and Glasgow, heavily propelled by the success of his debut single "Unspoken." There was an innocence to the soft voice that spoke to the believing heart in all of us. Holding out hope for a gentler and kinder world may not have always panned out, but Smith's honest lyricism made it feel a little less hopeless.

"Brother"a song about addiction takes the jagged edges of a chewed up stream of thoughts and smoothes them out into a soft piano-led melody. Searing strings slowly roll out the carpet as he hesitantly steps onto the affectionate chorus"Give me time / And ease my mind"before breaking out into a run amidst the rising instrumentals. It's poignant yet clean, leaving no demon swept under the rug. In one emotional swoop, Smith manages to empty that which felt burdened, cleanse that which felt dirty, and give voice to that which felt small.

Connect withAaron Smith:Spotify|Instagram|Twitter|Facebook

Read the original post:
Aaron Smith is reaching out for a "Brother" in a time of need - EARMILK

Dispute over baseball’s originator rages on pointlessly – you might as well ask: who invented fire? – Telegraph.co.uk

Posted on by

On the spot, the officials decided they needed a figurehead to harness this patriotism and naturally, to stamp down those damned Limeys and for the Great Creator they looked no further than Doubleday, a heroic major general from the Civil War. They shamelessly formed a commission and, as their overwhelming evidence, they held up a single letter sent in by a pal of Doubleday who insisted that he was present when Doubleday, as a schoolboy, persuaded his mates to try out his new rules in a friendly slog on a cow pasture in the middle of Cooperstown.

That New York village boasts only 2,000 inhabitants, but is a household name in the country because of the association. Doubleday Field yes, the poor cows were turfed out when the farm was inevitably developed still stages exhibition matches and two blocks up the road, the National Baseball Hall of Fame has welcomed more than 17 million visitors.

And what makes it all the more confusing is in that Hall of Fame there is no mention of Doubleday but a plaque honouring Cartwright as, guess what, The Father of Baseball.

So whose side are you on: Alexanders or Abners? Or maybe you are sane and recognise that entire sports cannot be created like say, the telephone or the lightbulb, in a Eureka! moment.

Read this article:
Dispute over baseball's originator rages on pointlessly - you might as well ask: who invented fire? - Telegraph.co.uk

PASTOR’S CORNER: Celebrate the Wonder of The Resurrection on Easter – Monroe County Reporter

Posted on by

We have just celebrated Palm Sunday. It is the final Sunday of Lent, the beginning of Holy Week, and the Kingship of Christ before he was crucified. Easter Sunday is the celebration of the resurrection of Jesus Christ.

The wonder of the resurrection may increase your curiosity or doubt about life and death. Neither of which can be fully explained or understood.

Christians know from the gospel that Jesus rose from the dead on the third day following his crucifixion. St. Paul said to the Corinthians, Resurrection was like a seed you sow, it never comes up until it first dies.

This may be interpreted as man has to undergo a change. We must pull off mortality and put on immortality.

1 Corinthians 15:20 says: But Christ has indeed been raised from the dead, the first fruits of those who have fallen asleep. Some may interpret this as meaning that he is an example of what the resurrection is like.

1 John 3:2 says: Dear friends, now we are children of God, and what we will be has not yet been made known. But we know that when he appears, we shall be like him, for we shall see him as he is.

Evidence at the grave proves that Christ did rise. Pilates seal was broken, the stone was rolled away, and the grave was found empty.

The resurrection of Christ marks the triumph of good over evil, sin and death. The wonder of the resurrection is that it proves that those who trust in God and accept Christ will be raised from the dead, that religion and worship will not be in vain.

According to St. Paul:

Acts 17:24: The God who made the world and everything in it is the Lord of heaven and earth and does not live in temples built by hands.

Acts 17:25: And he is not served by human hands, as if he needed anything, because he himself gives all men life and breath and everything else.

Acts 17:26: From one man he made every nation of men, that they should inhabit the whole earth; and he determined the times set for them and the exact places where they should live.

Acts 17:27: God did this so that men would seek him and perhaps reach out for him and find him, though he is not far from each one of us.

Acts 17:28: For in him we live and move and have our being.

Acts 17:29: Therefore since we are Gods offspring, we should not think that the divine being is like gold or silver or stone-an image made by mans design and skill.

Easter Sunday is the greatest of all days for it gives the world the gospel message of good news. It establishes the kingdom of heaven on earth and paves the way for the great commission set forth as follows:

Matthew 28:19-20: Therefore go and make disciples of all nations, baptizing them in the name of the Father and the Son and the Holy Spirit, and teaching them to obey everything I have commanded you. And surely I am with you always, to the very end of the age.

Rev. Clarence Thrower is pastor to the Forsyth Parish United Methodist Church and serves three congregations: Kynette UMC, 266 Martin Luther King Jr. Dr., Forsyth; Hopewell UMC, 483 Hopewell Road, Forsyth; Rocky Mount UMC, 1387 Highway 41 South, Barnesville.The Pastors Corner is sponsored by the Monroe County Ministerial Association, which meets on the second Thursday of each month at 8:30 a.m. at Christ United Methodist Church, 417 N. Frontage Road, Forsyth.

Go here to see the original:
PASTOR'S CORNER: Celebrate the Wonder of The Resurrection on Easter - Monroe County Reporter

MLB Writer Predicts Whose Jersey Number Red Sox Will Retire Next – NESN

Posted on by

Two candidates stand out from the rest in the race toward Boston Red Sox immortality.

MLB.coms Ian Browne last week named Dwight Evans and Roger Clemens as the players whose jersey numbers the Red Sox most likely will retire next. Clemens won the Cy Young Award three times and was Bostons ace for most of his 13-year tenure with the team in the 1980s and 1990s. Evans was a three-time All-Star and earned eight Gold Gloves during the 19 years he spent with the Red Sox in the 1970s and 1980s.

From a statistical standpoint, Roger Clemens is the obvious choice to be the next Red Sox player to have his number retired, Browne wrote. But the Rockets alleged association with PEDs makes it a cloudy issue for the Red Sox. Dwight Evans was an exemplary player for Boston for 19 years, making his No. 24 a candidate to get retired, as well.

Browne also includes Red Sox second baseman Dustin Pedroia and former pitcher Luis Tiant among other potential candidates to be the 12th number Boston retires.

The numbers of Joe Cronin (4), Ted Williams (9), Bobby Doerr (1), Carl Yastrzemski (8), Carlton Fisk (27), Johnny Pesky (6), Jim Rice (14), Wade Boggs (26), Pedro Martinez (45), David Ortiz (34) and Jackie Robinson (42) hang at Fenway Park in honor of their invaluable contributions to the Red Sox and Major League Baseball.

Thumbnail photo via Bob DeChiara/USA TODAY Sports Images

Read more from the original source:
MLB Writer Predicts Whose Jersey Number Red Sox Will Retire Next - NESN

Top 12 LSU Sports Events of the Decade: #9 2017 College World Series – And The Valley Shook

Posted on by

Since 2009 and LSUs last national title, LSU baseball has been consistently great. LSU has won seven SEC titles (four tournament titles and three regular season crowns), been a regular in the Supers, and made several trips to Omaha.

LSU even had great teams who could have competed for the title but suffered some bad luck along the way: 2012 was bedeviled by the weather against Stony Brook messing with the rotation, 2014 had some crazy bounces go bad against Houston, 2015 just couldnt figure out TCU. But the programs best chance at adding a date to the Intimidator came in 2017.

A loaded roster with such greats as Alex Lange and Kramer Robertson added a ton of freshmen talent: Josh Smith, Zach Smith, and Eric Walker especially.

LSU won the SEC regular season and tournament titles, and after dropping a midweek game to Tulane April 25, LSU rolled off a 12-2 record to close out the season, including winning all of their final seven games. LSU swept three of their final four series and then rolled through Hoover in four games, winning by a combined score of 35-5.

LSU continued its roll in the Baton Rouge Regional as well as the Supers against Mississippi St. LSU won nine straight games to make it to Omaha, and won its first game in Omaha as well, running the streak to ten.

The Tigers made it to the final series in Omaha by taking it the hard way. LSU had to beat #1 Oregon St. twice after dropping their first meeting 13-1. The Tigers responded and rolled into the final series by winning 3-1 and 6-1 decisions against the top ranked team in the nation.

Then came hated Florida.

Due to their run through the losers bracket, LSU had to burn their staff and couldnt start either of their lethal one-two punch of Lange and Jared Poche in Game 1. If LSU could get through Game 1, they could then get to their twin aces, and maybe win the title.

Florida jumped out to 3-0 lead and while LSU rallied, they never could close that gap. LSU had a rally in the eighth, but twin baserunning errors cost LSU two outs, and the rally fell short, 4-3.

In Game Two, LSU fell behind early again, and again, a late rally was defused by baserunning errors. Jake Slaughter was ruled out sliding into a players legs rather than the bag, meaning runner interference, sending Josh Smith back to third, taking away the tying run. Twice, LSU got runners on the corners in the late innings, and the team came away with nothing. LSU would fall 6-1 to not just any conference rival, but a program that truly ratcheted up the hatred with LSU over the past decade.

This was a great LSU team. There was no Rally Possum or can of corn or any other mystical totem. This was a team that simply had talent. They knew they were good and went for it. And they fell just short.

Worse, injuries derailed Eric Walker and Josh Smiths career at LSU. A team that seemed on the precipice of multiple runs to Omaha has instead not been back to the college baseballs most hollowed grounds.

That is the story of LSU baseball in the 10s: a very good program that was frustratingly close to immortality, but still a step away. They still remain that step away today. The run was great, there just wasnt enough magic.

Continue reading here:
Top 12 LSU Sports Events of the Decade: #9 2017 College World Series - And The Valley Shook

Amid a global pandemic, the Christian story of Easter shows us the power of hope – The Guardian

Posted on by

In the spring of 1963, the Southern Christian Leadership Conference was engaged in a campaign to defeat Jim Crow laws in Birmingham, Alabama.

As they approached the Easter weekend that year, no victory was in sight. But Dr Martin Luther King Jr knew there was something in the logic of Easter that suggested the way to victory might be counterintuitive. He decided to go to jail on Good Friday and stay there through the Easter weekend. He would not be free to preach a sermon on the holiest day of the Christian year, but he would pen his famous Letter from a Birmingham Jail as he waited to see a way forward.

In the midst of this worlds deepest darkness, the Christian story of the resurrection points towards the power of hope. As we weather a global pandemic, Easter offers a moment for us to reflect on the role of suffering and the possibility of radical solidarity.

Over the past month we have entered a new reality where despair is ever-present and fear pervasive. The death toll keeps rising, and instead of honest leadership we have a president who uses press conferences as political rallies. Trump might remind us of Pontius Pilate, who came from a well-known family and oversaw a tense, violent relationship with the Jewish minority of Jesus day. America today is not unlike the Roman Empire in which Christ was crucified as an insubordinate revolutionary.

Suffering is not anathema to Christians. In the Christian story, Jesus the son of the creator of the universe willingly undergoes a painful, bloody, public death. It is the last sacrifice, so that others do not need to continue the bloodletting. This is an astounding idea, a reversal of all our dominant values, our hunger for immortality, for power, for pleasure above all else. The crucifixion is the story of Jesus ultimate sacrifice and solidarity with the world.

But the story does not end with death. It ends with resurrection, an unbelievable miracle, and with the Holy Spirit persisting in a global community.

Can we come together as a global community today? As we take hope in the Easter story, we must also take the lessons of Christs life, which was spent in radical communion with the poor and sick.

The Poor Peoples Campaign: A National Call for Moral Revival has taken up the campaign begun by Martin Luther King Jr and others in 1968, which was itself a revival of the early churchs commitment to the least of these. We stand for the 140 million poor and low-income people who were left out of Congresss Covid-19 relief package: the 60 million workers who do not have paid sick leave, the 25 million with no health insurance, the 72 million who already have medical debt, the 8 million to 11 million people who are homeless, the 11 million undocumented immigrants who will receive no support. Often, in the midst of Americas obsession with the middle class, we forget those who have nothing. But Christ did not forget them.

And, as we seek solutions to this virus at home, we must remember its global reach. Indias 1.3 billion people are all in a 21-day lockdown. In Africa, the difficulty of social distancing in dense areas, paired with underlying conditions caused by malnutrition, could portend a devastating toll. As developing countries become harder hit, people are faced with the choice of infection or starvation.

Meanwhile, there is little interest in the United States for increasing aid abroad. On the contrary, industrial nations expect to bring in tens of billions in debt payments in 2020. The International Monetary Fund, aid organizations and world leaders are calling on creditors to suspend these payments. But there is much more that could be done. Many of the same leaders, including the IMF leadership and Nobel laureate economists, have called for the IMF to help countries through this crisis by providing, as it did in 2009, large amounts of debt-free special drawing rights. We could end the illegal sanctions on countries like Iran and Venezuela, which target civilians and have caused tens of thousands of deaths. Or we could make a commitment to ensuring that when a vaccine is found, it will be available to all.

American leaders have not taken any of these actions and we should not be surprised. This is the way of a civilization that has lost touch with its own humanity. It is the sign of a civilization that cannot last. But Christs life and death reminds us that we must continue the struggle. The resurrection reminded Christs followers that the death of the body is not the ultimate evil. On the contrary, it is the death of the soul, the death of our ability to see clearly what is right, which is far more devastating.

Christs life was an indictment of the Roman Empire and ultimately he was executed for his revolutionary protests. Pontius Pilate washed his hands before ordering the crucifixion, much like western governments might wash their hands today as they turn away from the suffering they could have avoided.

This Easter, the resurrection offers an indictment of empires and leaders that have become cruel in their hunger for power. But it also offers us a path forward. Though empires rise and fall, our ability to love and care for one another persists. When we press on in solidarity with those who are suffering, even when a way forward is not clear, we prepare ourselves to receive the good news of this season.

The Rev Dr William J Barber II is president of Repairers of the Breach and co-chair of the Poor Peoples Campaign

Dr Leah Hunt-Hendrix is a writer and co-founder of Way to Win

View original post here:
Amid a global pandemic, the Christian story of Easter shows us the power of hope - The Guardian

Role of Cuban science and biotechnology against coronavirus addressed – OnCubaNews

Posted on by

The president of BioCubaFarma, Eduardo Martnez, highlighted in the Mesa Redonda television program that in the fight against the coronavirus, his institution has a plan that covers different aspects, one of which is to guarantee the medicines designed for the protocols. He ensured their availability for patients who could be diagnosed, even in the worst case scenario.

He said that BioCubaFarma has also joined the production of soaps, disinfectants, hydroalcoholic solutions and protection means. He added that the antiviral action of interferon has been shown to be effective in treating the disease, along with other products developed by the biopharmaceutical industry. He said that many countries had asked Cuba for support in the supply of medicines. To date, 62 nations have requested interferon.

He insisted that asymptomatic patients constitute the fundamental cause of the spread of the epidemic; hence the importance of mass screening to identify suspects and isolate them. It is an international and local challenge, he said. This April 12, more than 2,000 tests were made in Cuba to diagnose the disease.

For his part, the director of the Finlay Vaccine Institute, Dr. Vicente Vrez, reported that even though the search for a vaccine will take time, there are other options to improve patients immune systems.

Cuba, he said, today has two vaccines used to fight both cancer and allergies, and they will start being applied to risk groups. Their purpose is aimed at strengthening peoples immune system. He explained that several researchers are working on a project aimed at finding out the incidence of these vaccines in patients to prevent them from developing a serious condition.

However, he said that the most important thing was social isolation, the use of the facemask and eyeglasses. All this makes it possible to put up a barrier against the virus and decrease the viral load in case of illness.

The director of the Center for Genetic Engineering and Biotechnology, Dr. Mara del Carmen Domnguez Orta, said that the institution has a research base of 20 years. A specific product, Molecule 258, is intended to regulate peoples immune systems and control inflammation of the organs without generating immunosuppression.

It has been applied, she said, in three critically ill patients at the IPK and the Naval Hospital with positive results, but, she pointed out, it is only used when there are no other options and with the prior consent of family members.

She stressed that this medicine is not a cure, but a therapeutic alternative, hence the importance of complying with prevention measures.

Lastly, Dr. Gerardo Guilln Nieto, director of Biomedical Research at the Center for Genetic Engineering and Biotechnology, said that the vaccine to strengthen innate immunity to COVID-19 is in the final phase of study.

The vaccine, which is applied sublingually, enhances immunity to the entry of the virus, he said, explaining that the samples analyzed after the application of the drug confirm that it stimulates the molecules that mark the activation of the innate immune system.

That vaccine will be favorable to the most vulnerable groups and will help them stimulate the immune response against the virus.

The rest is here:
Role of Cuban science and biotechnology against coronavirus addressed - OnCubaNews

The Global Biotechnology Reagents Market is expected to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period -…

Posted on by

Global Biotechnology Reagents Market 2020-2024 The analyst has been monitoring the biotechnology reagents market and it is poised to grow by $ 37. 87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period.

New York, April 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biotechnology Reagents Market 2020-2024" - https://www.reportlinker.com/p04821786/?utm_source=GNW Our reports on biotechnology reagents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of high-throughput and novel technologies and high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, the presence of high-throughput and novel technologies is anticipated to boost the growth of the market as well. The biotechnology reagents market analysis includes technology segments and geographic landscapes

The biotechnology reagents market is segmented as below: By Technology Chromatography In-vitro diagnostics Polymerase chain reaction Cell culture Others

By Geographic Landscapes APAC Europe North America ROW

This study identifies the increasing R&D investments by federal agencies and biotechnology firms as one of the prime reasons driving the biotechnology reagents market growth during the next few years. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our biotechnology reagents market covers the following areas: Biotechnology reagents market sizing Biotechnology reagents market forecast Biotechnology reagents market industry analysis

Read the full report: https://www.reportlinker.com/p04821786/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original post here:
The Global Biotechnology Reagents Market is expected to grow by $ 37.87 bn during 2020-2024 progressing at a CAGR of 8% during the forecast period -...

Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? – InvestorsObserver

Posted on by

The 72 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, IOVAs 72 overall rating means the stock scores better than 72 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock has risen 13.99% while the S&P 500 is unchanged 0% as of 9:50 AM on Tuesday, Apr 14. IOVA is higher by $4.23 from the previous closing price of $30.23 on volume of 285,317 shares. Over the past year the S&P 500 is down -4.95% while IOVA is higher by 209.06%. IOVA lost -$1.59 per share the over the last 12 months.

To screen for more stocks like IOVA click here.

See more here:
Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? - InvestorsObserver

Biotechnology Algae Cultivation Process (Micro Algae) Market Competitive Analysis and Top Profiling Forecasts to 2026 | Cellana, LGem, Solix Biofuels,…

Posted on by

Biotechnology Algae Cultivation Process (Micro Algae) Market Forecast 2020-2026

The Global Biotechnology Algae Cultivation Process (Micro Algae) 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Biotechnology Algae Cultivation Process (Micro Algae) analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

The key manufacturers covered in this report are: Cellana, LGem, Solix Biofuels, Ecoduna, Seambiotic, Algenol Biofuels, DENSO, Solazyme, Sapphire Energy, Cyanotech, Mialgae, and Neoalgae

This report also includes the overall and comprehensive study of the Biotechnology Algae Cultivation Process (Micro Algae) with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Biotechnology Algae Cultivation Process (Micro Algae) industry and provides data for making strategies to increase the market growth and effectiveness.

Development policies and plans are discussed as well as Manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Biotechnology Algae Cultivation Process (Micro Algae) . Various factors positively impacting the growth of the Biotechnology Algae Cultivation Process (Micro Algae) in the leading region are also discussed in the report. The global Biotechnology Algae Cultivation Process (Micro Algae) is also segmented on the basis of types, end users, geography and other segments.

Objective of Studies:

To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Biotechnology Algae Cultivation Process (Micro Algae) market.

To provide insights about factors affecting the market growth. To analyze the Biotechnology Algae Cultivation Process (Micro Algae) market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

To provide country level analysis of the market with respect to the current market size and future prospective.

To provide country level analysis of the market for segment by application, product type and sub-segments.

To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Biotechnology Algae Cultivation Process (Micro Algae) market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get Complete Report with Detailing TOC at Discounted Rate :https://www.reportsandmarkets.com/reports/global-biotechnology-algae-cultivation-process-micro-algae-market-2020-by-company-regions-type-and-application-forecast-to-2025?utm_source=jewishlifenews&utm_medium=15

Table of Content:

1 Study Coverage

2 Executive Summaries

3 Breakdown Data by Manufacturers

4 Breakdown Data by Type

5 Breakdown Data by Application

6 North America

7 Europe

8 Asia Pacific

9 Central & South America

Applications

10 Middle East and Africa

11 Company Profiles

12 Future Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

14 Value Chain and Sales Channels Analysis

15 Research Findings and Conclusion

16 Appendix

About us

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Person

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Here is the original post:
Biotechnology Algae Cultivation Process (Micro Algae) Market Competitive Analysis and Top Profiling Forecasts to 2026 | Cellana, LGem, Solix Biofuels,...

There are now 70 coronavirus vaccines in development, as the race to find treatments also gathers pace – CNBC

Posted on by

Scientists around the world are scrambling to find a vaccine the ultimate Covid-19 panacea.

There are now 70 candidate vaccines in development, up from to 44 on March 20, according to a document from WHO published Saturday. Experts expect it to take between 12 and 18 months to get a vaccine approved for mass use.

Of the 70 Covid-19 vaccines in development, only three are currently in clinical trials, meaning they are being tested on humans. Clinical trials are designed to assess the safety and efficacy of a new drug and consist of several phases, each involving more patients.

China's CanSino Biological, in partnership with the Beijing Institute of Biotechnology, is in the lead, with the only candidate vaccine currently in phase two trials. U.S. players Moderna and Inovio Pharmaceuticals are the other two developers testing vaccines on humans and both are currently in phase one. The remaining 67 potential vaccines are still only in the pre-clinical trial stage.

To bridge the gap between now and then when a vaccine is approved scientists continue to search for effective treatments, with efforts focused on several existing drugs.

British health-care giant AstraZeneca has joined this effort, announcing today that it would start a clinical trial to assess the potential of Calquence, a drug already approved for the treatment of leukaemia, in the treatment of the immune response associated with Covid-19. The trial is expected to open for enrolment in the coming days in the U.S. and several countries in Europe.

An Israeli scientist works at a laboratory at the MIGAL Research Institute in Kiryat Shmona in the upper Galilee in northern Israel on March 1, 2020 where efforts are underway to produce a vaccine against the COVID-19 coronavirus adapted from another for infectious bronchitis virus.

Jalaa Marey | AFP | Getty Images

Separately, there has been some encouraging news on Gilead's remdesivir, a drug originally developed to treat Ebola. New data published April 10 in the New England Journal of Medicine revealed that 68% of 53 hospitalized patients showed improvement after taking the drug. However, this was not a controlled study (rather, the data came from a compassionate use program which is where experimental drugs are offered to patients who have a disease with no authorized therapies), so experts urge caution when interpreting these findings.

Meanwhile, concerns are mounting around the safety of anti-malaria drugs chloroquine and hydroxychloroquine, touted by U.S. President Donald Trump as promising treatments. News emerged over the weekend that a chloroquine trial in Brazil was cut short after researchers found a high dose was associated with an irregular heartbeat.

Speaking at a coronavirus briefing in Geneva Monday, WHO Executive Director of the Health Emergencies Programme Dr. Michael Ryan commented: "The medical and research community are really taking the potential of hydroxychloroquine seriously and chloroquine seriously, and it's currently (involved) in a number of different trials."

However he added: "There is no empirical evidence, there is no evidence from randomized control trials that it works, and clinicians have also been cautioned to look out for side effects of the drug."

Read more:
There are now 70 coronavirus vaccines in development, as the race to find treatments also gathers pace - CNBC

$5.6 Bn High-performance Liquid Chromatography (HPLC) Market by Product, Application and Region – Forecast to 2025 – ResearchAndMarkets.com – Yahoo…

Posted on by

The "High-performance Liquid Chromatography (HPLC) Market by Product (Instruments (Systems, Detectors), Consumables (Columns, Filters), and Accessories), Application (Clinical Research, Diagnostics, Forensics), Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The report analyzes the HPLC market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

The global HPLC market is projected to reach USD 5,679.6 million by 2025 from USD 4,540.2 million in 2020, rising at a CAGR of 4.6%.

The key factors driving the growth of this market include the high sensitivity and accuracy of the HPLC technique, the growing importance of HPLC tests in drug approvals, improving the popularity of hyphenated techniques, and increasing pharmaceutical R&D spending. However, the high cost of HPLC systems is expected to restrict market growth to a certain extent.

Adoption of HPLC Instrument is expected to increase during the forecast period.

The acceptance of HPLC instruments is expected to rise due to the growing prevalence of patented studies and clinical trials. Growth in the research & development of pharmaceutical, biotechnology, food industry, agricultural industry, cosmetics, diagnostics, and forensic sciences will drive the growth of this segment. Consumables will also show a higher growth rate during the forecast period.

The clinical research segment will grow at the highest rate during the forecast period.

An increase in drug development studies, testing for raw materials, analysis of carbon, hydrogen, nitrogen, sulfur, chlorine, and oxygen in organic compounds and determining the presence of impurities has created a demand for advanced analysis equipment. An increase in research in various countries and a growth in clinical trial studies shows growth opportunities for this market.

The market in North America is projected to witness the highest growth rate during the forecast period (2020-2025).

North America is expected to account for the largest share of the global HPLC market. Market growth in this region is driven primarily by the increase in the funding for R&D, a growing number of preclinical activities by CROs and pharmaceutical companies, and the increasing food and agricultural industry in Canada. On the other hand, Asia-Pacific is projected to have the highest growth rate in the forecast period. The high growth rate of the Asian region can be attributed to factors such as extensive sales of biosimilars and generics in Japan, and the growth in the pharma and biotech sectors in India and China are some of the major factors driving the growth of the HPLC market in this region.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

4.1 High-Performance Liquid Chromatography Market Overview

4.2 Geographic Analysis: North American HPLC Market, by Product

4.3 HPLC Market Share, by Product, 2020 vs. 2025

4.4 HPLC Market Share, by Application, 2020 vs. 2025

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.1.1 High Sensitivity and Accuracy of the HPLC Technique

5.2.1.2 Growing Popularity of Hyphenated Techniques

5.2.1.3 Growing Importance of HPLC Tests in Drug Approvals

5.2.1.4 Increasing Pharmaceutical R&D Spending

5.2.2 Restraints

5.2.2.1 High Cost of Equipment

5.2.2.2 Dearth of Skilled Professionals

5.2.3 Opportunities

5.2.3.1 Increasing Use of Chromatography in the Purification of Monoclonal Antibodies

5.2.3.2 Emerging Markets in the Asia Pacific Region

5.2.4 Challenges

5.2.4.1 Extensive Requirements in Developing Systems that Generate Pressure Above 20,000 PSI

5.2.4.2 Lack of Long-Term Reproducibility

6 High-Performance Liquid Chromatography Market, by Product

6.1 Introduction

6.2 Instruments

6.2.1 HPLC Systems

6.2.1.1 HPLC Systems Dominated the Instruments Market in 2019

6.2.2 Pumps

6.2.2.1 Rising Demand for High-Pressure Pumps to Drive Market Growth

6.2.3 Detectors

6.2.3.1 Need for the Precise Detection of Minute Analyte Concentration to Boost Market Growth

Story continues

6.2.4 Fraction Collectors

6.2.4.1 Technological Advancements to Drive the Demand for Fraction Collectors

6.3 Consumables

6.3.1 Columns

6.3.1.1 Growth in R&D to Boost the HPLC Columns Market

6.3.1.2 Reversed-Phase HPLC Columns

6.3.1.3 Ion-Exchange HPLC Columns

6.3.1.4 Normal Phase/Hydrophilic Interaction HPLC Columns

6.3.1.5 Other HPLC Columns

6.3.2 Filters

6.3.2.1 Need for Efficient Filters is High As they Increase the Lifespan of Expensive Analytical Columns

6.3.3 Vials

6.3.3.1 Vial Selection is an Important Step in Chromatography

6.3.4 Tubes

6.3.4.1 Material Improvements in Tubes to Support Market Growth

6.4 Accessories

7 High-Performance Liquid Chromatography Market, by Application

7.1 Introduction

7.2 Clinical Research Applications

7.2.1 Growth in the Pharmaceutical and Biotechnology Industries to Support the Growth of this Application Segment

7.3 Diagnostic Applications

7.3.1 Rising Need to Determine Metabolites and Analytes to Boost Market Growth

7.4 Forensic Applications

7.4.1 US is the Largest Market for the Forensic Applications of HPLC

7.5 Other Applications

8 High-Performance Liquid Chromatography Market, by Region

8.1 Introduction

8.2 North America

8.2.1 US

8.2.1.1 US Accounted for the Largest Share of the North American Market

8.2.2 Canada

8.2.2.1 Growth in the Food and Agricultural Sectors to Support Market Growth in Canada

8.3 Europe

8.3.1 Germany

8.3.1.1 Increasing Life Science Research to Aid Market Growth in Germany

8.3.2 UK

8.3.2.1 Growth in the Biotechnology Sector to Drive Market Growth in the UK

8.3.3 France

8.3.3.1 Faster Approvals for Clinical Trials to Drive the Demand for HPLC in France

8.3.4 Italy

8.3.4.1 Growth in the Biotechnology and Pharmaceutical Industries to Support Market Growth in Italy

8.3.5 Spain

8.3.5.1 Growth in the Biotechnology Industry to Drive Market Growth in Spain

8.3.6 Rest of Europe

8.4 Asia Pacific

8.4.1 Japan

8.4.1.1 Rising Production of Biosimilars and Generics to Support Market Growth in Japan

8.4.2 China

8.4.2.1 Growth in the Biotechnology Sector to Support Market Growth in China

8.4.3 India

8.4.3.1 Growing Pharmaceutical Sector to Support Market Growth in India

8.4.4 Rest of Asia Pacific

8.5 Rest of the World

8.5.1 Middle East and Africa

More:
$5.6 Bn High-performance Liquid Chromatography (HPLC) Market by Product, Application and Region - Forecast to 2025 - ResearchAndMarkets.com - Yahoo...

Orgenesis to acquire assets of Tamir Biotechnology and its anti-viral platform ranpirnase for $19M – Proactive Investors USA & Canada

Posted on by

Orgenesis plans to combine ranpirnase with its Bioxome technology for enhanced payload delivery directly to cells

Inc () has entered into an agreement to acquire the assets of Tamir Biotechnology Inc including its broad-spectrum anti-viral platform ranpirnase.

The acquisition will be completed for total stock and cash consideration valued at about $19 million based on the value of the stock at closing, according to a statement.

Orgenesis said it plans to combine ranpirnase with its co-developed Bioxome technology for enhanced payload delivery directly to cells.

TamirBio is a clinical stage anti-viral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions.

TamirBios ranpirnase, its lead asset, is a ribonuclease (RNase),a member of the superfamily of enzymes that catalyze the degradation of RNA, and mediate several essential biological activities, including the regulation of cell proliferation, maturation, differentiation, and cell death.

Orgenesis said it is a potential candidate for the development of therapeutics for life-threatening diseases, including viral and autoimmune diseases, that require anti-proliferative and apoptotic properties.

TamirBios first target is the human papilloma virus (HPV), the worldwide leading cause of genital warts. The companys lead asset, topical ranpirnase, was evaluated in a Phase I/II clinical trial targeting genital warts. The Phase I/II study demonstrated the clear clinical effect of ranpirnase. Additional clinical trials are currently being planned.

Orgenesis and TamirBio plan to combine ranpirnase with Bioxomes, which have demonstrated the ability to fuse with cell membranes and deliver an intracellular cargo, in a similar manner to natural exosomes.

Bioxomes can carry selected therapeutic cargo inside the target cells when loaded with predesignated genetic material, proteins, signaling molecules and drugs, as these mimic the natural membrane fusion capacity of exosomes. Orgenesis and TamirBio believe the combination of the two platforms will result in enhanced efficacy and anti-viral results.

READ:Orgenesis and ExcellaBio develop a breakthrough manufacturing process for bioxomes

Combining TamirBios broad antiviral platform, ranpirnase, with Bioxomes could result in an enhanced payload delivery into cells, said Orgenesis CEO Vered Caplan.

In independent third-party testing, ranpirnase has shown anti-viral activity in multiple viruses. Additionally, over 1,000 patients have been dosed with ranpirnase in previous cancer/mesothelioma clinical trials. Ranpirnase demonstrated a strong safety and tolerability profile that should help accelerate the approval pathway.

Caplan added: We believe combining ranpirnase with the Bioxome platform has the potential to become a potent and powerful combination given the natural intracellular trafficking abilities of Bioxomes. We look forward to testing a variety of additional anti-viral therapies in the near future.

Jamie Sulley, president of TamirBio, pointed out that ranpirnase has already demonstrated preclinical antiviral activity in such viral diseases as HPV, HIV, Ebola, and SARS.

Not only do we believe Orgenesis will help advance ranpirnase through the clinic using their global development platform, but by combining ranpirnase with the Bioxome technology, we believe we can deliver ranpirnase through a more effective delivery mechanism, Sulley said.

Germantown, Maryland-based Orgenesis is a vertically integrated biopharmaceutical company with expertise in developing advanced cell therapies and manufacturing.

Contact the author: [emailprotected]

Follow him on Twitter @PatrickMGraham

The rest is here:
Orgenesis to acquire assets of Tamir Biotechnology and its anti-viral platform ranpirnase for $19M - Proactive Investors USA & Canada

Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19 and the Start of Phase 1 – BioSpace

Posted on by

MIAMI, April 13, 2020 /PRNewswire/ --Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an orally available antiviral compound, EIDD-2801, to begin human testing. This action by the MHRA allowed Ridgeback to commence Phase 1 in the UK on Friday April 10th.

"We are thankful to the amazing team at MHRA for the careful and expeditious consideration that led to clearance of our application," said Dr. Wayne Holman, Co-Founder of Ridgeback Biotherapeutics. "In this time of great need we were very pleased to collaborate with MHRA and appreciate the advice and guidance we received. As a result, Ridgeback was able to initiate screening at our Phase 1 site in the UK the very next day."

EIDD-2801 is a direct acting anti-viral nucleoside analogue. Essentially, EIDD-2801 tricks RNA viruses into including the wrong building blocks as it tries to reproduce itself. This leads to dramatically reduced levels of virus in animals infected with a wide variety of RNA viruses when treated with EIDD-2801. EIDD-2801 has been shown to treat MERS and SARS (two severe coronavirus infections) in animals when given after an infection has been established. When given prophylactically EIDD-2801 is able to prevent significant manifestations of disease in animals challenged with MERS and SARS.

"We believe if the animal data for severe coronaviruses is replicated in human trials that EIDD-2801 has the potential to safely treat COVID-19 with a short oral course of therapy that reduces the severity of disease and hopefully prevents the need for hospitalization and the need for ventilator support. We are grateful to our partners at DRIVE and to our scientific collaborators at UNC and Vanderbilt for all of the work it took to bring this project from an idea to patients. An orally available antiviral medication has the ability to change the course of this pandemic," said Wendy Holman, Co-founder and CEO of Ridgeback Biotherapeutics.

Ridgeback and DRIVE signed a partnership agreement in March 2020 with the focused mission of advancing EIDD-2801 through clinical development and to optimizing availability during the current COVID-19 pandemic.

"We are focused not only on the clinical development but also ramping up commercial supply at risk in advance of what we hope will be future positive clinical data," says Wendy Holman, CEO of Ridgeback Biotherapeutics. "Ridgeback has a history of pursuing manufacturing at risk in advance of positive clinical data. Our experience gives us a unique perspective on what types of partnerships are necessary in order to advance programs as efficiently as possible. We are thrilled that our partners at DRIVE share our same vision. The teams at Ridgeback and DRIVE have been working around the clock, 7 days a week in order to advance this program. I am so thankful to our employees and partners for their tireless efforts to advance the EIDD-2801 program."

About EIDD-2801:EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus.

About Ridgeback Biotherapeutics LP:Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and emerging infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions.

About DRIVE:DRIVE is a non-profit LLC wholly owned by Emory University and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVE's mission is to discover and develop antiviral drugs for emerging infections, pandemic threats, and biodefense (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis). Because these diseases are major threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVE's executive team, led by George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ridgeback-biotherapeutics-announces-mhra-clearance-to-begin-human-testing-of-eidd-2801-in-the-uk-for-covid-19-and-the-start-of-phase-1-301039312.html

SOURCE Ridgeback Biotherapeutics LP

View original post here:
Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19 and the Start of Phase 1 - BioSpace

White Biotechnology Market Share, Global Industry Outlook by Types, Applications, and End-User Analysis Industry Size, Growth Forecast to 2020-2025 -…

Posted on by

This detailed report on White Biotechnology market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. This comprehensive research- documentary on global White Biotechnology market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global White Biotechnology market. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global White Biotechnology market.

Top Leading Key Players are:

Solazyme Inc., Novozymes, Global Bioenergies, Amyris, BioAmber, Metabolic Explorer, Deinove, Evolva, Fermentlag, Codexis and many more

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/117

Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on White Biotechnology market. All the notable White Biotechnology market specific dimensions are studied and analyzed at length in the report to arrive at conclusive insights. Also, the competitive landscape of the White Biotechnology market is also evaluated at length in the report, to identify and analyze leading service providers.

Additionally, the competitive landscape of the White Biotechnology market is also evaluated at length in the report, to identify and analyze leading service providers. These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. Additionally, a dedicated section on regional overview of the White Biotechnology market is also included in the report to identify lucrative growth hubs.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/white-biotechnology-market

Besides these aforementioned factors and attributes of the White Biotechnology market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this White Biotechnology market a highly profitable. Other vital factors related to the White Biotechnology market such as scope, growth potential, profitability, and structural break-down have been innately roped in this White Biotechnology report to accelerate market growth.

Even further in the report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate. Further as the report progresses, a dedicated section on regional overview of the White Biotechnology market is also included in the report to identify lucrative growth hubs.

For Any Query on the White Biotechnology Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/117

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
White Biotechnology Market Share, Global Industry Outlook by Types, Applications, and End-User Analysis Industry Size, Growth Forecast to 2020-2025 -...

Global Food Biotechnology Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2025 – NJ MMA News

Posted on by

A leading research firm MarketsandResearch.biz added the latest industry report entitled Global Food Biotechnology Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2025 offers comprehensive research updates and information related to market growth, demand, opportunities in the global Food Biotechnology market. The report provides a close summary of the major segments within the industry. The quickest, as well as the slowest market segments, are lined properly during this report. The study comprises market analysis on a worldwide scale covering present and traditional growth analysis, competitive analysis, and also the expansion prospects of the central regions. Factors related to this market such as raw material affluence, financial stability, technological development, trading policies, and increasing demand boosting the market growth are further covered in the report.

This report also includes the cost and profit status of global Food Biotechnology and marketing status, Market growth drivers and challenges in this market. It analyzes the region-wise industrial environment, regulatory structure, competitive landscape, raw material resources that might influence the global industry. Additionally, provides in-depth analysis and insights into developments impacting businesses and enterprises on the global and regional level. Moreover, the report evaluates market size, industry status and forecast, competition landscape and growth opportunity. It categorizes the global market by companies, region, type, and end-use industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/5969

Market Report Offers Comprehensive Assessment of:

Global Food Biotechnology market executive summary, market overview, key market trends, key success factors, market demand/consumption analysis, industry analysis & forecast 2020-2025 by type, application, and region, market structure analysis, competition landscape, company share, and company profiles, assumptions, and research methodology.

This market research report on the global market analyzes the growth prospects for the key vendors operating in this market space including ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies Ltd, Dow AgroSciences LLC, DuPont Pioneer, Evogene Ltd, Hy-Line International, KWS Group, Monsanto, Origin Agritech Limited, Syngenta AG,

Each geographic segment of the global Food Biotechnology market has been independently surveyed along with pricing, distribution and demand data for geographic market notably: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Segment by product type, this report focuses on consumption, market share, and growth rate of the market in each product type and can be divided into Transgenic Crops, Synthetic Biology Derived Products,

Segment by application, this report focuses on consumption, market share, and growth rate of the market in each application and can be divided into Animals, Plants, Other

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/5969/global-food-biotechnology-market-2020-by-manufacturers-countries-type-and-application-forecast-to-2025

The entire product consumption growth rate across the applicable regions as well as consumption market share is described in the report. It tracks and analyzes competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Food Biotechnology market.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

The rest is here:
Global Food Biotechnology Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2025 - NJ MMA News